Shingles Treatments
Shingles Treatments

Shingles Treatments Comprehensive Study by Type (Antiviral Medications, Narcotic Medications, Anti-Inflammatory Medications, Antihistamines, Anticonvulsants, Creams, Others), Route of Administration (Oral, Injection), End User (Clinics, Hospitals, Diagnostic Centers, Home Care Settings) Players and Region - Global Market Outlook to 2026

Shingles Treatments Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 216 Pages 198 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
The study covers a detailed analysis segmented by key business segments i.e. by type (Antiviral Medications, Narcotic Medications, Anti-Inflammatory Medications, Antihistamines, Anticonvulsants, Creams and Others) and major geographies. Research Analyst at AMA predicts that United States and European Players will contribute to the maximum growth of Global Shingles Treatments market throughout the predicted period.

What is Shingles Treatments?
Shingles is a reactivation of the chickenpox virus in the body, causing a painful rash. Anyone who had chickenpox may develop shingles. It is still unidentified what reactivates the virus. The use of various drugs to treat shingles enables to provide relief from rashes. As per sources, about one million instances of shingles are detailed each year in the United States, and around one in every three individuals in the United States will create shingles in their lifetime. The risk of shingles increases with age, with most cases reported among people over 40 years old. This will drive the market growth in the forecast period

The competition is expected to become even more intense in the years to come due to entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Shingles Treatments market analysis report suggests strategies Players can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, including:
  • GlaxoSmithKline PLC (United Kingdom)
  • Foamix Pharmaceuticals Ltd (United States)
  • Epiphany Biosciences Inc (United States)
  • Merck & Co. (United States)
  • Astellas Pharma Inc.(Japan)
  • Novartis International AG (Switzerland)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Beijing Minhai Biotechnology Co. (China)
  • GeneOne Life Science, Inc. (South Korea)
  • NAL Pharmaceuticals Ltd. (United States)
  • TSRL, Inc. (United States)


Several companies are leaning toward inorganic growth strategies such as mergers & acquisitions to improve their market share and brand presence globally. The market is highly fragmented and consists of several manufacturers at the global and regional level competing to increase their market share in the respective regions

Market Trend
R&D investment in Drug Development
Restraints
  • High Cost Of Antibodies Is Restraining Vaccination

Opportunities
Developing Interest For Antiviral Prescriptions And Over-The-Counter Pain Medicines and High Demand From Emerging Countries

Key highlights of the Global Shingles Treatments market Study:
• CAGR of the market during the forecast period 2020-2026
• In-depth information on growth factors that will accelerate the Shingles Treatments market in next few years.
• Detailed Insights on futuristic trends and changing consumer behaviour
• Forecast of the Global Shingles Treatments market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Shingles Treatments Players

Transformation and Important Trigegrs:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Shingles Treatments market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Shingles Treatments market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Shingles Treatments Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. Where the Shingles Treatments industry is heading?
Shingles Treatments Market is heading robustly to achieve new growth cycle.

2. Is Shingles Treatments market is changing from growth to value?
The Concentration Rate of Global Shingles Treatments market is dominated by United States and European Players to generate healthy valuation by 2026.

3. Who are the key players profiled in the Shingles Treatments Market?
Companies that are profiled in Global Shingles Treatments Market are GlaxoSmithKline PLC (United Kingdom), Foamix Pharmaceuticals Ltd (United States), Epiphany Biosciences Inc (United States), Merck & Co. (United States), Astellas Pharma Inc.(Japan), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Beijing Minhai Biotechnology Co. (China), GeneOne Life Science, Inc. (South Korea), NAL Pharmaceuticals Ltd. (United States) and TSRL, Inc. (United States) etc.
Report Objectives / Segmentation Covered
By Type
  • Antiviral Medications
  • Narcotic Medications
  • Anti-Inflammatory Medications
  • Antihistamines
  • Anticonvulsants
  • Creams
  • Others
By Route of Administration
  • Oral
  • Injection

By End User
  • Clinics
  • Hospitals
  • Diagnostic Centers
  • Home Care Settings

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Pervasiveness Of Shingles
      • 3.2.2. Demand For Antiviral to Reduce The Shingles Rash
    • 3.3. Market Challenges
      • 3.3.1. Lack Of Guidance From Specialists In Choosing Appropriate Anticoagulant
    • 3.4. Market Trends
      • 3.4.1. R&D investment in Drug Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Shingles Treatments, by Type, Route of Administration, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Shingles Treatments (Value)
      • 5.2.1. Global Shingles Treatments by: Type (Value)
        • 5.2.1.1. Antiviral Medications
        • 5.2.1.2. Narcotic Medications
        • 5.2.1.3. Anti-Inflammatory Medications
        • 5.2.1.4. Antihistamines
        • 5.2.1.5. Anticonvulsants
        • 5.2.1.6. Creams
        • 5.2.1.7. Others
      • 5.2.2. Global Shingles Treatments by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Injection
      • 5.2.3. Global Shingles Treatments by: End User (Value)
        • 5.2.3.1. Clinics
        • 5.2.3.2. Hospitals
        • 5.2.3.3. Diagnostic Centers
        • 5.2.3.4. Home Care Settings
      • 5.2.4. Global Shingles Treatments Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Shingles Treatments: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Foamix Pharmaceuticals Ltd (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Epiphany Biosciences Inc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Astellas Pharma Inc.(Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis International AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Beijing Minhai Biotechnology Co. (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GeneOne Life Science, Inc. (South Korea)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. NAL Pharmaceuticals Ltd. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. TSRL, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Shingles Treatments Sale, by Type, Route of Administration, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Shingles Treatments (Value)
      • 7.2.1. Global Shingles Treatments by: Type (Value)
        • 7.2.1.1. Antiviral Medications
        • 7.2.1.2. Narcotic Medications
        • 7.2.1.3. Anti-Inflammatory Medications
        • 7.2.1.4. Antihistamines
        • 7.2.1.5. Anticonvulsants
        • 7.2.1.6. Creams
        • 7.2.1.7. Others
      • 7.2.2. Global Shingles Treatments by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Injection
      • 7.2.3. Global Shingles Treatments by: End User (Value)
        • 7.2.3.1. Clinics
        • 7.2.3.2. Hospitals
        • 7.2.3.3. Diagnostic Centers
        • 7.2.3.4. Home Care Settings
      • 7.2.4. Global Shingles Treatments Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Shingles Treatments: by Type(USD Million)
  • Table 2. Shingles Treatments Antiviral Medications , by Region USD Million (2015-2020)
  • Table 3. Shingles Treatments Narcotic Medications , by Region USD Million (2015-2020)
  • Table 4. Shingles Treatments Anti-Inflammatory Medications , by Region USD Million (2015-2020)
  • Table 5. Shingles Treatments Antihistamines , by Region USD Million (2015-2020)
  • Table 6. Shingles Treatments Anticonvulsants , by Region USD Million (2015-2020)
  • Table 7. Shingles Treatments Creams , by Region USD Million (2015-2020)
  • Table 8. Shingles Treatments Others , by Region USD Million (2015-2020)
  • Table 9. Shingles Treatments: by Route of Administration(USD Million)
  • Table 10. Shingles Treatments Oral , by Region USD Million (2015-2020)
  • Table 11. Shingles Treatments Injection , by Region USD Million (2015-2020)
  • Table 12. Shingles Treatments: by End User(USD Million)
  • Table 13. Shingles Treatments Clinics , by Region USD Million (2015-2020)
  • Table 14. Shingles Treatments Hospitals , by Region USD Million (2015-2020)
  • Table 15. Shingles Treatments Diagnostic Centers , by Region USD Million (2015-2020)
  • Table 16. Shingles Treatments Home Care Settings , by Region USD Million (2015-2020)
  • Table 17. South America Shingles Treatments, by Country USD Million (2015-2020)
  • Table 18. South America Shingles Treatments, by Type USD Million (2015-2020)
  • Table 19. South America Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 20. South America Shingles Treatments, by End User USD Million (2015-2020)
  • Table 21. Brazil Shingles Treatments, by Type USD Million (2015-2020)
  • Table 22. Brazil Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 23. Brazil Shingles Treatments, by End User USD Million (2015-2020)
  • Table 24. Argentina Shingles Treatments, by Type USD Million (2015-2020)
  • Table 25. Argentina Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 26. Argentina Shingles Treatments, by End User USD Million (2015-2020)
  • Table 27. Rest of South America Shingles Treatments, by Type USD Million (2015-2020)
  • Table 28. Rest of South America Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 29. Rest of South America Shingles Treatments, by End User USD Million (2015-2020)
  • Table 30. Asia Pacific Shingles Treatments, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Shingles Treatments, by Type USD Million (2015-2020)
  • Table 32. Asia Pacific Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 33. Asia Pacific Shingles Treatments, by End User USD Million (2015-2020)
  • Table 34. China Shingles Treatments, by Type USD Million (2015-2020)
  • Table 35. China Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 36. China Shingles Treatments, by End User USD Million (2015-2020)
  • Table 37. Japan Shingles Treatments, by Type USD Million (2015-2020)
  • Table 38. Japan Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 39. Japan Shingles Treatments, by End User USD Million (2015-2020)
  • Table 40. India Shingles Treatments, by Type USD Million (2015-2020)
  • Table 41. India Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 42. India Shingles Treatments, by End User USD Million (2015-2020)
  • Table 43. South Korea Shingles Treatments, by Type USD Million (2015-2020)
  • Table 44. South Korea Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 45. South Korea Shingles Treatments, by End User USD Million (2015-2020)
  • Table 46. Taiwan Shingles Treatments, by Type USD Million (2015-2020)
  • Table 47. Taiwan Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 48. Taiwan Shingles Treatments, by End User USD Million (2015-2020)
  • Table 49. Australia Shingles Treatments, by Type USD Million (2015-2020)
  • Table 50. Australia Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 51. Australia Shingles Treatments, by End User USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Shingles Treatments, by Type USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Shingles Treatments, by End User USD Million (2015-2020)
  • Table 55. Europe Shingles Treatments, by Country USD Million (2015-2020)
  • Table 56. Europe Shingles Treatments, by Type USD Million (2015-2020)
  • Table 57. Europe Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 58. Europe Shingles Treatments, by End User USD Million (2015-2020)
  • Table 59. Germany Shingles Treatments, by Type USD Million (2015-2020)
  • Table 60. Germany Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 61. Germany Shingles Treatments, by End User USD Million (2015-2020)
  • Table 62. France Shingles Treatments, by Type USD Million (2015-2020)
  • Table 63. France Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 64. France Shingles Treatments, by End User USD Million (2015-2020)
  • Table 65. Italy Shingles Treatments, by Type USD Million (2015-2020)
  • Table 66. Italy Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 67. Italy Shingles Treatments, by End User USD Million (2015-2020)
  • Table 68. United Kingdom Shingles Treatments, by Type USD Million (2015-2020)
  • Table 69. United Kingdom Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 70. United Kingdom Shingles Treatments, by End User USD Million (2015-2020)
  • Table 71. Netherlands Shingles Treatments, by Type USD Million (2015-2020)
  • Table 72. Netherlands Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 73. Netherlands Shingles Treatments, by End User USD Million (2015-2020)
  • Table 74. Rest of Europe Shingles Treatments, by Type USD Million (2015-2020)
  • Table 75. Rest of Europe Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 76. Rest of Europe Shingles Treatments, by End User USD Million (2015-2020)
  • Table 77. MEA Shingles Treatments, by Country USD Million (2015-2020)
  • Table 78. MEA Shingles Treatments, by Type USD Million (2015-2020)
  • Table 79. MEA Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 80. MEA Shingles Treatments, by End User USD Million (2015-2020)
  • Table 81. Middle East Shingles Treatments, by Type USD Million (2015-2020)
  • Table 82. Middle East Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 83. Middle East Shingles Treatments, by End User USD Million (2015-2020)
  • Table 84. Africa Shingles Treatments, by Type USD Million (2015-2020)
  • Table 85. Africa Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 86. Africa Shingles Treatments, by End User USD Million (2015-2020)
  • Table 87. North America Shingles Treatments, by Country USD Million (2015-2020)
  • Table 88. North America Shingles Treatments, by Type USD Million (2015-2020)
  • Table 89. North America Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 90. North America Shingles Treatments, by End User USD Million (2015-2020)
  • Table 91. United States Shingles Treatments, by Type USD Million (2015-2020)
  • Table 92. United States Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 93. United States Shingles Treatments, by End User USD Million (2015-2020)
  • Table 94. Canada Shingles Treatments, by Type USD Million (2015-2020)
  • Table 95. Canada Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 96. Canada Shingles Treatments, by End User USD Million (2015-2020)
  • Table 97. Mexico Shingles Treatments, by Type USD Million (2015-2020)
  • Table 98. Mexico Shingles Treatments, by Route of Administration USD Million (2015-2020)
  • Table 99. Mexico Shingles Treatments, by End User USD Million (2015-2020)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Shingles Treatments: by Type(USD Million)
  • Table 112. Shingles Treatments Antiviral Medications , by Region USD Million (2021-2026)
  • Table 113. Shingles Treatments Narcotic Medications , by Region USD Million (2021-2026)
  • Table 114. Shingles Treatments Anti-Inflammatory Medications , by Region USD Million (2021-2026)
  • Table 115. Shingles Treatments Antihistamines , by Region USD Million (2021-2026)
  • Table 116. Shingles Treatments Anticonvulsants , by Region USD Million (2021-2026)
  • Table 117. Shingles Treatments Creams , by Region USD Million (2021-2026)
  • Table 118. Shingles Treatments Others , by Region USD Million (2021-2026)
  • Table 119. Shingles Treatments: by Route of Administration(USD Million)
  • Table 120. Shingles Treatments Oral , by Region USD Million (2021-2026)
  • Table 121. Shingles Treatments Injection , by Region USD Million (2021-2026)
  • Table 122. Shingles Treatments: by End User(USD Million)
  • Table 123. Shingles Treatments Clinics , by Region USD Million (2021-2026)
  • Table 124. Shingles Treatments Hospitals , by Region USD Million (2021-2026)
  • Table 125. Shingles Treatments Diagnostic Centers , by Region USD Million (2021-2026)
  • Table 126. Shingles Treatments Home Care Settings , by Region USD Million (2021-2026)
  • Table 127. South America Shingles Treatments, by Country USD Million (2021-2026)
  • Table 128. South America Shingles Treatments, by Type USD Million (2021-2026)
  • Table 129. South America Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 130. South America Shingles Treatments, by End User USD Million (2021-2026)
  • Table 131. Brazil Shingles Treatments, by Type USD Million (2021-2026)
  • Table 132. Brazil Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 133. Brazil Shingles Treatments, by End User USD Million (2021-2026)
  • Table 134. Argentina Shingles Treatments, by Type USD Million (2021-2026)
  • Table 135. Argentina Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 136. Argentina Shingles Treatments, by End User USD Million (2021-2026)
  • Table 137. Rest of South America Shingles Treatments, by Type USD Million (2021-2026)
  • Table 138. Rest of South America Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 139. Rest of South America Shingles Treatments, by End User USD Million (2021-2026)
  • Table 140. Asia Pacific Shingles Treatments, by Country USD Million (2021-2026)
  • Table 141. Asia Pacific Shingles Treatments, by Type USD Million (2021-2026)
  • Table 142. Asia Pacific Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 143. Asia Pacific Shingles Treatments, by End User USD Million (2021-2026)
  • Table 144. China Shingles Treatments, by Type USD Million (2021-2026)
  • Table 145. China Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 146. China Shingles Treatments, by End User USD Million (2021-2026)
  • Table 147. Japan Shingles Treatments, by Type USD Million (2021-2026)
  • Table 148. Japan Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 149. Japan Shingles Treatments, by End User USD Million (2021-2026)
  • Table 150. India Shingles Treatments, by Type USD Million (2021-2026)
  • Table 151. India Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 152. India Shingles Treatments, by End User USD Million (2021-2026)
  • Table 153. South Korea Shingles Treatments, by Type USD Million (2021-2026)
  • Table 154. South Korea Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 155. South Korea Shingles Treatments, by End User USD Million (2021-2026)
  • Table 156. Taiwan Shingles Treatments, by Type USD Million (2021-2026)
  • Table 157. Taiwan Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 158. Taiwan Shingles Treatments, by End User USD Million (2021-2026)
  • Table 159. Australia Shingles Treatments, by Type USD Million (2021-2026)
  • Table 160. Australia Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 161. Australia Shingles Treatments, by End User USD Million (2021-2026)
  • Table 162. Rest of Asia-Pacific Shingles Treatments, by Type USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 164. Rest of Asia-Pacific Shingles Treatments, by End User USD Million (2021-2026)
  • Table 165. Europe Shingles Treatments, by Country USD Million (2021-2026)
  • Table 166. Europe Shingles Treatments, by Type USD Million (2021-2026)
  • Table 167. Europe Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 168. Europe Shingles Treatments, by End User USD Million (2021-2026)
  • Table 169. Germany Shingles Treatments, by Type USD Million (2021-2026)
  • Table 170. Germany Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 171. Germany Shingles Treatments, by End User USD Million (2021-2026)
  • Table 172. France Shingles Treatments, by Type USD Million (2021-2026)
  • Table 173. France Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 174. France Shingles Treatments, by End User USD Million (2021-2026)
  • Table 175. Italy Shingles Treatments, by Type USD Million (2021-2026)
  • Table 176. Italy Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 177. Italy Shingles Treatments, by End User USD Million (2021-2026)
  • Table 178. United Kingdom Shingles Treatments, by Type USD Million (2021-2026)
  • Table 179. United Kingdom Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 180. United Kingdom Shingles Treatments, by End User USD Million (2021-2026)
  • Table 181. Netherlands Shingles Treatments, by Type USD Million (2021-2026)
  • Table 182. Netherlands Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 183. Netherlands Shingles Treatments, by End User USD Million (2021-2026)
  • Table 184. Rest of Europe Shingles Treatments, by Type USD Million (2021-2026)
  • Table 185. Rest of Europe Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 186. Rest of Europe Shingles Treatments, by End User USD Million (2021-2026)
  • Table 187. MEA Shingles Treatments, by Country USD Million (2021-2026)
  • Table 188. MEA Shingles Treatments, by Type USD Million (2021-2026)
  • Table 189. MEA Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 190. MEA Shingles Treatments, by End User USD Million (2021-2026)
  • Table 191. Middle East Shingles Treatments, by Type USD Million (2021-2026)
  • Table 192. Middle East Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 193. Middle East Shingles Treatments, by End User USD Million (2021-2026)
  • Table 194. Africa Shingles Treatments, by Type USD Million (2021-2026)
  • Table 195. Africa Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 196. Africa Shingles Treatments, by End User USD Million (2021-2026)
  • Table 197. North America Shingles Treatments, by Country USD Million (2021-2026)
  • Table 198. North America Shingles Treatments, by Type USD Million (2021-2026)
  • Table 199. North America Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 200. North America Shingles Treatments, by End User USD Million (2021-2026)
  • Table 201. United States Shingles Treatments, by Type USD Million (2021-2026)
  • Table 202. United States Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 203. United States Shingles Treatments, by End User USD Million (2021-2026)
  • Table 204. Canada Shingles Treatments, by Type USD Million (2021-2026)
  • Table 205. Canada Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 206. Canada Shingles Treatments, by End User USD Million (2021-2026)
  • Table 207. Mexico Shingles Treatments, by Type USD Million (2021-2026)
  • Table 208. Mexico Shingles Treatments, by Route of Administration USD Million (2021-2026)
  • Table 209. Mexico Shingles Treatments, by End User USD Million (2021-2026)
  • Table 210. Research Programs/Design for This Report
  • Table 211. Key Data Information from Secondary Sources
  • Table 212. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Shingles Treatments: by Type USD Million (2015-2020)
  • Figure 5. Global Shingles Treatments: by Route of Administration USD Million (2015-2020)
  • Figure 6. Global Shingles Treatments: by End User USD Million (2015-2020)
  • Figure 7. South America Shingles Treatments Share (%), by Country
  • Figure 8. Asia Pacific Shingles Treatments Share (%), by Country
  • Figure 9. Europe Shingles Treatments Share (%), by Country
  • Figure 10. MEA Shingles Treatments Share (%), by Country
  • Figure 11. North America Shingles Treatments Share (%), by Country
  • Figure 12. Global Shingles Treatments share by Players 2020 (%)
  • Figure 13. Global Shingles Treatments share by Players (Top 3) 2020(%)
  • Figure 14. Global Shingles Treatments share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 18. Foamix Pharmaceuticals Ltd (United States) Revenue, Net Income and Gross profit
  • Figure 19. Foamix Pharmaceuticals Ltd (United States) Revenue: by Geography 2020
  • Figure 20. Epiphany Biosciences Inc (United States) Revenue, Net Income and Gross profit
  • Figure 21. Epiphany Biosciences Inc (United States) Revenue: by Geography 2020
  • Figure 22. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 24. Astellas Pharma Inc.(Japan) Revenue, Net Income and Gross profit
  • Figure 25. Astellas Pharma Inc.(Japan) Revenue: by Geography 2020
  • Figure 26. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 28. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 30. Beijing Minhai Biotechnology Co. (China) Revenue, Net Income and Gross profit
  • Figure 31. Beijing Minhai Biotechnology Co. (China) Revenue: by Geography 2020
  • Figure 32. GeneOne Life Science, Inc. (South Korea) Revenue, Net Income and Gross profit
  • Figure 33. GeneOne Life Science, Inc. (South Korea) Revenue: by Geography 2020
  • Figure 34. NAL Pharmaceuticals Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 35. NAL Pharmaceuticals Ltd. (United States) Revenue: by Geography 2020
  • Figure 36. TSRL, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. TSRL, Inc. (United States) Revenue: by Geography 2020
  • Figure 38. Global Shingles Treatments: by Type USD Million (2021-2026)
  • Figure 39. Global Shingles Treatments: by Route of Administration USD Million (2021-2026)
  • Figure 40. Global Shingles Treatments: by End User USD Million (2021-2026)
  • Figure 41. South America Shingles Treatments Share (%), by Country
  • Figure 42. Asia Pacific Shingles Treatments Share (%), by Country
  • Figure 43. Europe Shingles Treatments Share (%), by Country
  • Figure 44. MEA Shingles Treatments Share (%), by Country
  • Figure 45. North America Shingles Treatments Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GlaxoSmithKline PLC (United Kingdom)
  • Foamix Pharmaceuticals Ltd (United States)
  • Epiphany Biosciences Inc (United States)
  • Merck & Co. (United States)
  • Astellas Pharma Inc.(Japan)
  • Novartis International AG (Switzerland)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Beijing Minhai Biotechnology Co. (China)
  • GeneOne Life Science, Inc. (South Korea)
  • NAL Pharmaceuticals Ltd. (United States)
  • TSRL, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation